QuidelOrtho reported total revenue of $724 million for Q4 2025, with non-respiratory revenue growing 7% in constant currency and Labs revenue growing 8%. The company achieved an adjusted EBITDA margin of 21% and adjusted diluted EPS of $0.46. For the full year 2025, total revenue was $2.73 billion, with an adjusted EBITDA of $597 million.
Total revenue for Q4 2025 was $724 million, showing a 2.2% increase compared to the prior year.
Non-respiratory revenue, excluding Donor Screening, grew 7% in constant currency for Q4 2025.
Labs revenue increased by 8% as reported and 7% in constant currency during Q4 2025.
Adjusted diluted EPS for Q4 2025 was $0.46, with an adjusted EBITDA margin of 21%.
QuidelOrtho provided fiscal year 2026 financial guidance, projecting total revenues between $2.7 billion and $2.9 billion, adjusted EBITDA between $630 million and $670 million, and adjusted diluted EPS between $2.00 and $2.42. Free cash flow is expected to improve significantly, ranging from $120 million to $160 million.
Analyze how earnings announcements historically affect stock price performance